Kinaset Therapeutics Announces First Patient Dosed in Phase 2b PANAIRAMA Trial of frevecitinib (KN-002) in Patients with Severe Asthma

Source Summary

BOSTON--(BUSINESS WIRE)--Kinaset Therapeutics, a clinical-stage biopharmaceutical company developing inhaled therapeutics to treat serious respiratory diseases, today announced the first patient has been dosed in its Phase 2b clinical trial evaluating frevecitinib, a novel inhaled pan JAK inhibitor, in patients with severe asthma inadequately controlled despite treatment with medium-to-high dose inhaled corticosteroid long-acting beta agonist (ICS/LABA) therapy. PANAIRAMA is a randomized, doubl